EMRA-MED Arzneimittel GmbH (3263935) - search_results

actemra 20 mgml i.v.

roche pharmaceuticals (israel) ltd - tocilizumab - concentrate for solution for infusion - tocilizumab 20 mg/ml - tocilizumab - tocilizumab - actemra (tocilizumab), is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more dmards(disease modifying anti-rheumatic drugs) or tnf antagonists or in whom dmards cannot be used. actemra can be used alone or in combination with methotrexate or other dmards. actemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. actemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. actemra in combination with methotrexate (mtx) in indicated for the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.actemra is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 3 years of age and older.actemra is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

actemra

roche products (nz) ltd - tocilizumab 162mg; ; ; ; tocilizumab 162mg - solution for injection - 162 mg/0.9ml - active: tocilizumab 162mg excipient: arginine arginine hydrochloride histidine histidine hydrochloride monohydrate methionine polysorbate 80 water for injection active: tocilizumab 162mg excipient: arginine hydrochloride histidine histidine hydrochloride monohydrate methionine polysorbate 20 water for injection - actemra is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients: - in combination with methotrexate (mtx) in those not previously treated with mtx - in combination with methotrexate (mtx) or other non-biological disease modifying anti-rheumatic drugs (dmards) in case of either an inadequate response or intolerance to previous therapy with one or more dmards - as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. actemra has been shown to inhibit the progression of joint damage in adults, as measured by x-ray, when given in combination with methotrexate.

Իսրայել - անգլերեն - Ministry of Health

actemra 162 mg s.c.

roche pharmaceuticals (israel) ltd - tocilizumab - solution for injection - tocilizumab 162 mg / 0.9 ml - tocilizumab - - actemra in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease modifying anti rheumatic drugs (dmards) or tumor necrosis factor (tnf) antagonists. in these patients, actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. - actemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. - actemra in combination with methotrexate (mtx) in indicated for the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx - actemra (tocilizumab) is indicated for the treatment of giant cell arteritis (gca) in adult patients. - actemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. - actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. actemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.